Comparison of Efficacy Between Nab-Paclitaxel or Docetaxel Combined with Carboplatin as Neoadjuvant Therapy for HER2-Positive Breast Cancer
ObjectiveTo compare the efficacy of trastuzumab plus pertuzumab (HP) combined with either nab-paclitaxel plus carboplatin or docetaxel plus carboplatin as neoadjuvant therapy for HER2-positive breast cancer in real-world clinical practice. MethodsClinical data of HER2-positive breast cancer patients...
| 發表在: | Zhongliu Fangzhi Yanjiu |
|---|---|
| Main Authors: | , , , , |
| 格式: | Article |
| 語言: | 中文 |
| 出版: |
Magazine House of Cancer Research on Prevention and Treatment
2024-09-01
|
| 主題: | |
| 在線閱讀: | http://www.zlfzyj.com/cn/article/doi/10.3971/j.issn.1000-8578.2024.24.0147 |